Video

The Future of AI in Drug Discovery: How Artificial Intelligence is Generating Ideas for New Medicines

In this latest podcast episode from The Future Labs, Dr Jackie Hunter, our Board Director at BenevolentAI, explores how artificial intelligence is generating new ideas for new medicines, and cutting the time and cost of designing drugs to bring them to patients faster.

The development of new drugs and treatments is an extremely complicated and failure-prone process. As an example of the scale of the challenge - developing a drug and getting it to market can take 10-15 years and cost more than $2.5 billion. What’s more, the top selling drugs available today only work for 30-50% of the patients to whom they are prescribed.

Although technology has been an indispensable component of drug discovery for decades, patients are not yet authentically benefiting from its potential at it relates to the generation of  new and more effective treatments.

In this podcast, Jackie discuss how the high cost and decline in tangible outputs from drug R&D, has resulted in the need to seek out new inventive solutions to improve the efficiency of medicinal development. We explore a radically different approach - how building machine learning tools and applying artificial intelligence to drug discovery can create new ideas to be interpreted by scientists in the lab.

Listen to Jackie explain BenevolentAI’s approach to drug discovery and the progress we are making to better understand diseases and to develop treatments for the millions of patients that need them.

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
NeurIPS 2020: Meet the BenevolentAI team
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020